Design, Synthesis and X-Ray Crystallographic Studies of Alpha-Aryl Substituted Fosmidomycin Analogues as Inhibitors of Mycobacterium Tuberculosis 1-Deoxy-D-Xylulose-5-Phosphate ReductoisomeraseAndaloussi, M., Henriksson, L.M., Wieckowska, A., Lindh, M., Bjorkelid, C., Larsson, A.M.S., Iyer, H., Srinivasa, B.R., Bergfors, T., Unge, T., Mowbray, S.L., Larhed, M., Jones, T.A., Karlen, A.
(2011) J.Med.Chem 54: 4964
- PubMed: 21678907
- DOI: 10.1021/jm2000085
- Primary Citation of Related Structures:
- Also Cited By: 3ZHY, 3ZHZ, 3ZI0, 3ZHX
- PubMed Abstract:
- The 1.9 A Resolution Structure of Mycobacterium Tuberculosis 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase, a Potential Drug Target.
Henriksson, L.M.,Bjorkelid, C.,Mowbray, S.L.,Unge, T.
(2006) Acta Crystallogr.,Sect.D 62: 807
- Structures of Mycobacterium Tuberculosis 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Provide New Insights Into Catalysis.
Henriksson, L.M.,Unge, T.,Carlsson, J.,Aqvist, J.,Mowbray, S.L.,Jones, T.A.
(2007) J.Biol.Chem. 282: 19905
The natural antibiotic fosmidomycin acts via inhibition of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR), an essential enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. Fosmidomycin is active on Mycobacterium tuberculosis DXR ( ...
The natural antibiotic fosmidomycin acts via inhibition of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR), an essential enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. Fosmidomycin is active on Mycobacterium tuberculosis DXR (MtDXR), but it lacks antibacterial activity probably because of poor uptake. α-Aryl substituted fosmidomycin analogues have more favorable physicochemical properties and are also more active in inhibiting malaria parasite growth. We have solved crystal structures of MtDXR in complex with 3,4-dichlorophenyl substituted fosmidomycin analogues; these show important differences compared to our previously described forsmidomycin-DXR complex. Our best inhibitor has an IC(50) = 0.15 μM on MtDXR but still lacked activity in a mycobacterial growth assay (MIC > 32 μg/mL). The combined results, however, provide insights into how DXR accommodates the new inhibitors and serve as an excellent starting point for the design of other novel and more potent inhibitors, particularly against pathogens where uptake is less of a problem, such as the malaria parasite.
Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Biomedical Center, Box 574, SE-751 23 Uppsala, Sweden.